Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT04614194
- Locations
- 🇺🇸
Parkland Hospital, Dallas, Texas, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 186
- Registration Number
- NCT04606446
- Locations
- 🇺🇸
Thomas Jefferson University, Gibbon Building, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Investigational Drug Service, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 162
- Registration Number
- NCT04603183
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇮🇹Instituto Europeo di Oncologia, Milano, Italy
🇮🇹Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza, Torino, Italy
Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Shereen Rady Abou El-fetouh
- Target Recruit Count
- 110
- Registration Number
- NCT04590482
Letrozole in Patients With Hepatopulmonary Syndrome
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1
- Registration Number
- NCT04577001
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 65
- Registration Number
- NCT04551495
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇫🇷Institut Bergonié, Bordeaux, France
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 992
- Registration Number
- NCT04546009
- Locations
- 🇺🇸
Long Beach Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Orange Coast Memorial Medical Center, Fountain Valley, California, United States
🇺🇸Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1068
- Registration Number
- NCT04478266
- Locations
- 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸Investigational Site Number :8400013, Westwood, Kansas, United States
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04469764
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.